AID Logo

Directory >> Lawrence Corey, MD


Contact Information

Lawrence Corey, MD

  • Member
    Divisions of Vaccine and Infectious Disease, Clinical Research, and Public Health Sciences
    President and Director
    Fred Hutchinson Cancer Research Center
  • Professor, Departments of Medicine and Laboratory Medicine
  • Adjunct Professor, Departments of Pediatrics and Microbiology
    University of Washington

The research areas associated with Dr. Corey include:

  • Herpes group infections
  • Infections in the immunocompromised host, especially those undergoing bone marrow transplant
  • HIV vaccine development

The herpes virus research program at the University of Washington involves studies in HSV, CMV, HHV-6 and HHV-8. The genital HSV program has been the most longstanding, having had continuous NIH funding since 1978. This program involves clinical investigations of HSV reactivation and transmission, laboratory based studies on the cellular immunology of HSV, and characterization of HSV-HIV interactions. In the last few years, the laboratory has focused on developing an HSV vaccine by defining the T-cell responses to HSV, especially cytotoxic T-cell responses as a means of developing CTL-based vaccines for immunotherapy or prophylaxis of genital HSV. The laboratory based programs involve collaborations with Drs. Jia Zhu, Research Assistant Professor; David Koelle, Professor of Medicine; Keith Jerome, Professor of Laboratory Medicine and Head of the Diagnostic Virology Division; and Christine Posavad, Senior Scientist at the Fred Hutchinson Cancer Research Center. The Clinical Research Program in genital herpes is directed by Dr. Anna Wald, Professor of Medicine and Dr. Christine Johnston, Assistant Professor of Medicine. Dr. Wald is medical director of the Viral Disease Clinic, a specialty clinic dedicated to a wide range of clinical studies on HSV infection, including resolution frequency, vaccine efficacy and technology development.

The program in HHV-8 infection encompasses studies of the transmission of HHV-8 and the mechanism by which HHV-8 induces Kaposi's sarcoma. This work is done with Dr. Corey Casper, Associate Member at the Hutchinson Center. Clinical trials for HHV-8 prevention are conducted in the newly formed Uganda Program on Cancer and Infectious Diseases under the direction of Dr. Orem Jackson of the Uganda Cancer Institute and Dr. Corey Casper and Dr. Warren Phipps at the Fred Hutchinson Cancer Research Center.

The Vaccine and Infectious Disease Division (VIDD) of the Hutchinson Center is home to many researchers studying prevention of CMV and HHV-6 infections in the immunocompromised host and the role these infections play in the morbidity of HSCT. Dr. Michael Boeckh, Professor of Medicine, heads research on CMV infection in collaboration with Dr. Steven Pergam, Associate Professor in Medicine.

The HIV research program directed by Dr. Corey includes both laboratory and clinical investigation. Dr. Corey is the PI of the NIAID supported HIV Vaccine Trials Network (HVTN), a global network of clinical trial sites and laboratories dedicated to phase I-III trials of candidate HIV vaccines and other preventative and treatment options. Other faculty members involved in the effort are Drs. Juliana McElrath, Peter Gilbert, and Jim Kublin. Training opportunities for postdoctoral fellows interested in learning vaccine biology and clinical trial research are available within the network.

Selected Publications

Gray GE, Allen M, Moodie Z, Churchyard G, Bekker, L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG, on behalf of the HVTN 503/Phambili study team. Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomized, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011; 11(7): 507-15.
PubMed Abstract

Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010;107(44): 18973-8. PMCID: PMC2973882
PubMed Abstract

Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, Klock A, Jin L, Diem K, Koelle DM, Wald A, Robins H,Corey L. Immune surveillance by CD8aa+ skin-resident T cells in human herpes virus infection. Nature. 2013 May 23;497(7450):494-7. PMC3663925
PubMed Abstract

Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A,Corey L. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007; 204(3): 595-603.
PubMed Abstract

Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang M-L, Selke S, Stobernack H-P, Ruebsamen-Schaeff H and Birkmann A. Helicase-Primase Inhibitor Pritelivir for HSV-2 infection.N Eng J Med 2014 Jan 16;370(3):201-10
PubMed Abstract

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L on behalf of the HVTN 503 study team. Long Term Follow-up of the HVTN 503/Phambili Study, a phase 2b HIV vaccine trial, investigating an Ad5 HIV-1 gag/pol/nef Vaccine in South Africa. Lancet Infect Dis. 2014 Feb 20. pii: S1473-3099(14)70020-9.
PubMed Abstract


to top